The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists

(2018) Dana A. Emerson et al.   BIODRUGS

Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens

(2018) Jeremy D. Waight et al.   CANCER CELL

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

(2018) Xuexiang Du et al.   CELL RESEARCH

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

The promise and challenges of immune agonist antibody development in cancer

(2018) Patrick A. Mayes et al.   NATURE REVIEWS DRUG DISCOVERY

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

(2018) Randi B. Gombos et al.   PLoS One

Anti–CTLA-4 therapy requires an Fc domain for efficacy

(2018) Jessica R. Ingram et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4

(2018) Sergio A. Quezada et al.   CLINICAL CANCER RESEARCH

Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers-Letter

(2018) Roberto Ferrara et al.   CLINICAL CANCER RESEARCH

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer

(2017) Azharuddin Sajid Syed Khaja et al.   Frontiers in Immunology

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

(2016) Peter Ellmark et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors

(2016) Anna Fišerová et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

(2015) Anne Bertrand et al.   BMC Medicine

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

(2015) Zeynep Eroglu et al.   EUROPEAN JOURNAL OF CANCER

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

(2015) Anna Śledzińska et al.   Molecular Oncology

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

(2014) Linda C Sandin et al.   OncoImmunology

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

(2014) Ross Stewart et al.   Journal for ImmunoTherapy of Cancer

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients

(2013) H-B Jie et al.   BRITISH JOURNAL OF CANCER

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity

(2013) W. L. Redmond et al.   Cancer Immunology Research

Immunological Variation Between Inbred Laboratory Mouse Strains

(2011) R. S. Sellers et al.   VETERINARY PATHOLOGY

Overcoming immunological tolerance to melanoma: Targeting CTLA-4

(2010) F Stephen HODI   Asia-Pacific Journal of Clinical Oncology

Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

(2010) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA